Atlas Trials

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Clinical trial NCT02921789 · COMPLETED

Trial details

NCT number
NCT02921789
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Kidney TransplantationPrimary Focal Segmental Glomerulosclerosis (FSGS)
Start date
2017-05-22
Primary completion
2020-12-11
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.